Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | aspartyl proteinase, putative | 0.0443 | 0.1257 | 1 |
Plasmodium falciparum | plasmepsin II | 0.0443 | 0.1257 | 1 |
Echinococcus multilocularis | cathepsin d (lysosomal aspartyl protease) | 0.0443 | 0.1257 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0422 | 0.1067 | 0.6684 |
Plasmodium falciparum | plasmepsin I | 0.0443 | 0.1257 | 1 |
Toxoplasma gondii | aspartyl protease ASP1 | 0.0443 | 0.1257 | 0.1787 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.1382 | 1 | 1 |
Trichomonas vaginalis | Clan AA, family A1, cathepsin D-like aspartic peptidase | 0.0443 | 0.1257 | 0.5 |
Toxoplasma gondii | 1,3-beta-glucan synthase component protein | 0.1064 | 0.7038 | 1 |
Plasmodium falciparum | plasmepsin IV | 0.0443 | 0.1257 | 1 |
Echinococcus granulosus | cathepsin d lysosomal aspartyl protease | 0.0443 | 0.1257 | 1 |
Plasmodium falciparum | plasmepsin VI | 0.0443 | 0.1257 | 1 |
Schistosoma mansoni | memapsin-2 (A01 family) | 0.0954 | 0.6014 | 0.5538 |
Schistosoma mansoni | subfamily A1A unassigned peptidase (A01 family) | 0.0443 | 0.1257 | 0.0213 |
Loa Loa (eye worm) | hypothetical protein | 0.0443 | 0.1257 | 1 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0443 | 0.1257 | 0.1787 |
Plasmodium vivax | plasmepsin IV, putative | 0.0443 | 0.1257 | 1 |
Loa Loa (eye worm) | aspartic protease BmAsp-2 | 0.0443 | 0.1257 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | > 200 uM | Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay | ChEMBL. | 17194716 |
IC50 (binding) | > 200 uM | Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay | ChEMBL. | 17194716 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.